Evaluation of the effectiveness of a peptide-cytokine agent in the complex therapy of recurrent candidal vulvovaginitis
Background. The literature shows that up to 75% of women of reproductive age suffer at least one episode of acute candidal vulvovaginitis (CVV) in life, up to 45% report 2 cases or more, up to 20% experience recurrent (often complicated) course of this disease. Recurrent CVV requires a non-standard...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Berlin A.V.
2024-12-01
|
| Series: | Гинекология |
| Subjects: | |
| Online Access: | https://gynecology.orscience.ru/2079-5831/article/viewFile/643246/159193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background. The literature shows that up to 75% of women of reproductive age suffer at least one episode of acute candidal vulvovaginitis (CVV) in life, up to 45% report 2 cases or more, up to 20% experience recurrent (often complicated) course of this disease. Recurrent CVV requires a non-standard approach and the use of other treatment methods in addition to antimycotic agents.
Aim. To evaluate the effectiveness of the peptide-cytokine agent Superlymph in the complex therapy of recurrent CVV.
Materials and methods. The study included 90 patients which were divided into three groups. All patients underwent all stages of diagnosis and treatment. Group 1 (n=30) received standard of care with antimycotics + Superlymph 10 units twice a day vaginally for 10 days. Then without interruption, Superlymph 10 units once daily was administered vaginally for 10 days. Group 2 (n=30) included patients who received antifungal treatment with Superlymph 10 units twice a day vaginally for 10 days. Group 3 (n=30) included females who received standard antimycotic therapy without other drugs.
Results. Ten days after the start of therapy, the symptoms were completely relieved in 100% of patients in Groups 1 and 2, and 2 (6.7%) patients from Group 3 reported CVV recurrence. None of the patients in the study groups discontinued therapy due to adverse events, and all patients reported good or excellent tolerability. Six months after the end of therapy, the percent of Lactobacilli in the urogenital scraping according to the Femoflor-16 test was high in Groups 1 and 2 – 96.7% in patients of both groups. In Group 3, it was 83.3%. A high abundance of Candida spp. was not found in any of the patients in Groups 1 and 2, while in Group 3, it was found in 16.7% of patients.
Conclusion. The addition of Superlymph 10 units to the standard antimycotic systemic therapy during the exacerbation of CVV can significantly reduce the number of relapses in women within 6 months after the end of treatment. Complex therapy with Superlymph can be an alternative to fluconazole monotherapy in patients with recurrent CVV, particularly in women planning pregnancy. Superlymph can be used during pregnancy after consulting a doctor and following the prescribing information. |
|---|---|
| ISSN: | 2079-5696 2079-5831 |